ECE2021 Audio Eposter Presentations Adrenal and Cardiovascular Endocrinology (80 abstracts)
Hedi Chaker Hospital, Endocrinology, Sfax, Tunisia
Introduction
Recent studies in patients with Addisons disease have shown that this condition, even if treated, is fraught with significant morbidity and even excess mortality. The objective of our study was to determine the deleterious effects of long-term glucocorticoid replacement mainly on the metabolic level.
Methods
Retrospective study, carried out at the Endocrinology and Diabetology Department of Hédi Chaker Sfax University Hospital, which involved 32 patients with Addisons disease that has been evolving for more than 15 years.
Results
The average age was 58.53 years with a predominance of women. The mean duration of follow-up was 17.87 years. The hydrocortisone dose was initially 32.5 mg/d, at the end of 27.9 mg/d. There was gradual weight gain, an increase in body mass index and waist circumference. The prevalence of MS was 3.12% at diagnosis and 35.71% after treatment duration greater than 15 years. At the end of the follow-up, 28.57% of the obese patients against 7.14% at the discovery of the disease were noted, 25% of the hypertensive and type 2 diabetic patients all appeared throughout the follow-up, 42.85% of the dyslipidemic patients. Factors favoring the occurrence of the metabolic syndrome were the duration of the disease and the weight loss on discovery of the disease.
Conclusion
Adjustment of replacement therapy during Addisons disease is an issue in view of the morbidity and mortality associated with overdose. Regular monitoring and a personalized therapeutic approach are necessary to improve the prognosis of his patients.